MRK Merck
What matters nowUpdated 4 days ago
- The latest development is a Dutch court ruling that Keytruda SC infringes Halozyme's EP 2,797,622 patent, barring MSD BV from offering Keytruda SC in eight European countries; IV Keytruda is not covered and a separate US suit over Keytruda Qlex remains open 1.
- The pooled 24/7 venue price is 143.33, down 1.6% from the previous close of 145.68; the stock fell 2.7% on Sep 30 and 3.5% on Oct 5.
- Trailing revenue is $66.6B as of June 30, 2026, up 4.6% year on year (5.1% last quarter), with a 73.0% gross margin and $16.1B of free cash flow; Keytruda sales were $8.37B in Q2 2026, up 5%. EPS of $1.26 is down 80.6% year on year, net debt is $47.1B, and the P/E is 113.8 on a $353.6B market cap. Insiders sold nine times over 180 days for $30.0M, with no buys.
- Recent approvals and deals: the FDA added HYPERION data to the Winrevair label for newly diagnosed pulmonary arterial hypertension 2; Merck and Daiichi Sankyo withdrew the US application for ifinatamab deruxtecan in small cell lung cancer 3; and Merck licensed SciBrunch's preclinical KRAS G12D inhibitor SPR2015 for a $400M upfront payment, with a $400M pre-tax charge expected in Q3, about $0.13 per share 4.
- Next: the Q3 2026 sales and earnings call is on Oct 29 at 9:00 a.m. ET 5, and an oncology investor event in Madrid, timed to ESMO 2026, is on Oct 26.
Halozyme press release (PR Newswire, October 7, 2026) · Oct 7
Merck press release · Sep 22
Merck press release · Sep 25
Merck press release · Sep 28
Merck press release · Oct 1
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings↗ (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| binance perp MRKUSDT · 1 min ago | 146.37 | 0.00% | $141.5K | $95.6K | 0.0000% |
| bitget perp MRKUSDT · just now | 145.87 | −0.34% | $39.4K | $470.6K | 0.0000% |
| okx perp MRK-USDT-SWAP · stale | 146.66 | +0.20% | $92.5K | $124.0K | 0.0000% |
| bybit perp MRKUSDT · stale | 146.58 | +0.14% | $42.7K | $178.1K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
Dutch court finds Keytruda SC infringes Halozyme patent, barring sales in eight European countries
A Dutch patent court found that Merck's subcutaneous Keytruda infringes Halozyme's EP 2,797,622 patent and rejected Merck's argument that the patent is invalid.
Merck schedules third-quarter 2026 sales and earnings call for October 29
Merck announced its third-quarter 2026 sales and earnings conference call for 9:00 a.m.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor SPR2015 for $400M upfront
Merck signed an exclusive worldwide license with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor that is still preclinical.
Merck and Daiichi Sankyo withdraw US application for ifinatamab deruxtecan in small cell lung cancer
Merck and Daiichi Sankyo voluntarily withdrew the US Biologics License Application for ifinatamab deruxtecan (I-DXd) in previously treated extensive-stage small cell lung cancer.
FDA adds HYPERION data to Winrevair label for newly diagnosed pulmonary arterial hypertension
The FDA approved an updated Winrevair (sotatercept) label that adds Phase 3 HYPERION data for adults newly diagnosed with pulmonary arterial hypertension who are at intermediate to high risk of progression.
Japan approves Keytruda Qlex for subcutaneous use across all approved Keytruda indications
Japan approved Keytruda Qlex, the subcutaneous form of Keytruda, for every Keytruda indication already approved in Japan.
Intismeran autogene with KEYTRUDA beats Keytruda alone in Phase 3 melanoma trial
Merck and Moderna said the Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival, with the combination improving both over KEYTRUDA alone in patients with completely resected melanoma.
Merck and Moderna say personalized melanoma vaccine plus Keytruda met primary endpoint in Phase 3
Merck and Moderna announced topline Phase 3 INTerpath-001 results: intismeran autogene plus Keytruda beat Keytruda alone on recurrence-free survival in 1,137 patients with completely resected high-risk melanoma.
Merck executives DeLuca and Guindo sell 21,050 shares at about $130-131 on August 6
SEC Form 4 filings show two Merck executives sold stock on August 6, 2026, days after the second-quarter report.
Merck reports fiscal Q2 2026 results: revenue $16.61B, up 5% from a year earlier
Merck filed a Form 8-K with the SEC on Aug 4, 2026, 6:47 AM ET, reporting an event dated Aug 4, 2026.
Merck Q2 2026 sales rise 5% to $16.6B; 2026 EPS guidance cut to $2.66-2.76 on acquisition charges
Merck reported second-quarter 2026 sales of $16.61 billion, up 5% (4% excluding FX), with Keytruda and Keytruda Qlex at $8.37 billion.
Merck declares $0.85 quarterly dividend for the fourth quarter of 2026
Merck's board declared a quarterly dividend of $0.85 per share for the fourth quarter of 2026.
Merck and Gilead preview full Phase 3 data for once-weekly islatravir and lenacapavir HIV regimen
Merck and Gilead used a July 21 release to preview the full Phase 3 ISLEND results for the investigational once-weekly oral HIV regimen of islatravir and lenacapavir, ahead of late-breaking presentations on July 29 at AIDS 2026.
FDA approves Lipfendra (enlicitide), the first once-daily oral PCSK9 cholesterol medicine
The FDA approved Merck's Lipfendra (enlicitide) 20 mg tablets as an add-on to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
FDA approves Keytruda plus Padcev before and after surgery for cisplatin-eligible bladder cancer
The FDA approved Keytruda and Keytruda Qlex, each combined with Padcev, for adults with muscle-invasive bladder cancer who are eligible for cisplatin, given before cystectomy and continued after surgery.